13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001577524
Total reported value
$177.9M
$177.9M
9 檔
76.7%
The Q1 2026 SEC filing reveals that Sarissa Capital Management LP held a total portfolio value of $177.9M, covering 9 public equity positions.
In Q1 2026, Sarissa Capital Management LP adopted a defensive or profit-taking posture, trimming 5 positions and completely liquidating 0 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INVA | Innoviva Inc | Stock-Other | 31.50% | -7.36% | -24.33% | |
| 2 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 20.46% | +1.29% | -42.28% | |
| 3 | AMRN | Amarin CORP PLC -adr | Stock-Other | 15.35% | -0.35% | — | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 9.74% | +1.30% | -61.56% | |
| 5 | CYTK | Cytokinetics Inc | Stock-Healthcare | 9.56% | +1.39% | -42.32% | |
| 6 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 8.03% | +2.38% | -8.01% | |
| 7 | BHVN | Biohaven Ltd. | Stock-Other | 3.02% | +1.85% | +9.74% | |
| 8 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.05% | -0.58% | — | |
| 9 | VOR | Vor Biopharma Inc | Stock-Other | 0.29% | -0.03% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INVA | Innoviva Inc | +6.3% | -24.33% | Trim |
| 2 | AMRN | Amarin CORP PLC -adr | +4.9% | — | Unchanged |
| 3 | LNTH | Lantheus Holdings Inc | +2.6% | -8.01% | Trim |
| 4 | REGN | Regeneron Pharmaceuticals | +0.6% | — | Unchanged |
| 5 | BHVN | Biohaven Ltd. | +0.4% | +9.74% | Add |
| 6 | VOR | Vor Biopharma Inc | +0.1% | — | Unchanged |
| 7 | CYTK | Cytokinetics Inc | -1.7% | -42.32% | Trim |
| 8 | IRWD | Ironwood Pharmaceuticals Inc | -3.6% | -42.28% | Trim |
| 9 | NBIX | Neurocrine Biosciences Inc | -9.6% | -61.56% | Trim |
According to official SEC Form 13F filings, Sarissa Capital Management LP reported a total U.S. public equity portfolio value of $177.9M across 9 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INVA, IRWD, AMRN) accounted for 76.7% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
INVA
前期市值: $56.3M
During Q1 2026, Sarissa Capital Management LP's top holdings by market value included INVA (31.5%)、IRWD (20.5%)、AMRN (15.3%). The largest single position, INVA, represented 31.5% of total portfolio value.
In Q1 2026, Sarissa Capital Management LP made 6 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 5 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.